Home Clinical Trials Update

Clinical Trials Update

Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Pivotal Phase II Clinical Trial of Single Agent Loncastuximab Tesirine in Shows Positive Results...

Results from a pivotal 145-patient Phase II clinical trial of loncastuximab tesirine (ADCT-402; ADC Therapeutics) for the treatment of...

OBI-999, a Novel First-in-class ADC, Granted FDA Orphan Drug Designation for Pancreatic Cancer

OBI-999, a novel antibody-drug conjugate or ADC being developed by OBI Pharma, a Taiwan based biopharmaceutical company, has been...

Confirmatory Study of Mirvetuximab Soravtansine in Ovarian Cancer on Track to Start by Year-End

In a statement earlier today, ImmunoGen confirmed that the U.S. Food and Drug Administration (FDA) has advised that a...
Speakers and attendees during the morning sessions on Wednesday December 11, 2019. during the San Antonio Breast Cancer Symposium being held at the Henry B. Gonzalez Convention Center in San Antonio, TX. This year is the 42nd Anniversary of the meeting where over 7,500 physicians, researchers, patient advocates and healthcare professionals from over 90 countries attended the meeting which features the latest research on breast cancer treatment and prevention. Photo Courtesy 2019 © MedMeetingImages/Todd Buchanan

SABCS 2019: DESTINY-Breast01 Trial of Trastuzumab Deruxtecan Shows Positive Results in HER2+ Metastatic Breast...

Detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial (NCT03248492) of trastuzumab deruxtecan (DS-8201; fam-trastuzumab deruxtecan in...

ASH 2019: Findings from Phase I Study of IMGN632 Shows Potential in AML and...

New safety and efficacy findings from the dose escalation and expansion of the first-in-human trial of IMGN632 in patients...

Enfortumab Vedotin + Pembrolizumab to be Evaluated in Phase III Registration Trial in...

Enfortumab vedotin (also known as AGS-22ME; Seattle Genetics/Astellas), an antibody-drug conjugate (ADC), will be evaluated in a phase III...

Polatuzumab Vedotin Shows Complete Response in R/R Diffuse Large B-cell Lymphoma

Polatuzumab vedotin (Polivy™; Genentech/Roche) in combination with bendamustine (Treanda®; Cephalon/Teva Pharmaceutical) and rituximab (Rituxan®; Genentech/Roche) shows encouraging rates of...
Daiichi Sankyo, Basking Ridge, NJ. Courtesy: Daiichi Sankyo.

Daiichi Sankyo Starts First-in-Human Phase I/II Study Evaluating DS-7300

Daiichi Sankyo, in collaboration with and Sarah Cannon Research Institute, has started the first-in-human, open label, phase I/II study...

DREAMM-2 Trial Shows Positive Results for Belantamab Mafodotin in Multiple Myeloma

Earlier today positive headline results from the pivotal DREAMM-2 open-label, randomized study of two doses of belantamab mafodotin (GSK2857916),...
One red Dutch tulip

Trastuzumab Duocarmazine for Treatment of HER2-Expressing Breast Cancer

Trastuzumab duocarmazine* (SYD985; Synthon) is a novel antibody-drug conjugate composed of the recombinant humanized anti-epidermal growth factor receptor 2...